Volume 5 Issue 5
Sep.  2014
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2014  >  5(5): 308-313
Chen Huanwei, Deng Feiwen, Zhen Zuojun. Research on the oral nucleoside analogues monotherapy in the prevention of hepatitis B recurrence of patients after liver transplantation[J]. ORGAN TRANSPLANTATION, 2014, 5(5): 308-313. doi: 10.3969/j.issn.1674-7445.2014.05.010
Citation: Chen Huanwei, Deng Feiwen, Zhen Zuojun. Research on the oral nucleoside analogues monotherapy in the prevention of hepatitis B recurrence of patients after liver transplantation[J]. ORGAN TRANSPLANTATION, 2014, 5(5): 308-313. doi: 10.3969/j.issn.1674-7445.2014.05.010
shu

Research on the oral nucleoside analogues monotherapy in the prevention of hepatitis B recurrence of patients after liver transplantation

doi: 10.3969/j.issn.1674-7445.2014.05.010

  • Department of Hepatic Surgery, the First People's Hospital of Foshan, Foshan 528000, China

  • Received Date: 2014-05-22
  • Publish Date: 2014-09-15
    Abstract
  •   Objective   To explore the efficacy and safety of the oral nucleoside analogues monotherapy in the prevention of hepatitis B recurrence of patients after liver transplantation (LT).   Methods   Clinical data of 32 patients with hepatitis B-related disease undergoing LT in the First People's Hospital of Foshan in Guangdong Province from October 1999 to April 2014 were retrospectively analyzed. The patients were divided into two phase groups according to the source of donors. Phase 1 was from October 1999 to September 2007 when 6 patients receiving LT of non-heart-beating donors. The serum hepatitis B virus(HBV) markers of 6 donor livers were all negative. The serum hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) of the recipients before operation were all positive, including 2 cases combined with Hepatitis B e antigen (HBeAg) positive, 1 case combined with hepatitis B virus e antibody (anti-HBe) positive. The serum HBV deoxyribonucleic acid (DNA) of 5 recipients before LT were over 1 000 copies/ml and 1 case were below 1 000 copies/ml. All the patients in phase 1 group were given lamivudine (100 mg/d) monotherapy orally for the prevention of hepatitis B recurrence after LT. Phase 2 was from November 2011 to April 2014 when 26 patients receiving LT of donation after cardiac death including 1 case of combined liver-kidney transplantation. Six of the donor livers were with serum HBsAg positive and 20 cases negative. Fifteen cases were with hepatitis B surface antibody (anti-HBs) positive and 2 cases with HBeAg positive, 14 cases with anti-HBc positive and 5 with anti-HBe positive. The serum HBV DNA of 11 recipients before LT were over 500 copies/ml and 15 cases below 500 copies/ml. Twenty-five cases were given entecarvir 0.5 mg/d and 1 case telbivudine 600 mg/d monotherapy orally for the prevention of hepatitis B recurrence.   Results   The median follow-up time of the recipients in group phase 1 was 104 months. The serum HBsAg and HBV DNA were both negative in all recipients and no hepatitis B recurrence was observed till now. The median follow-up time of the recipients in group phase 2 was 50 weeks. Twenty cases received donor livers of negative HBsAg, in which 1 case had transient positive HBsAg 39 weeks after LT and became negative later. The patient receiving combined liver-kidney transplantation suffered hepatitis B recurrence 28 weeks after LT but HBV DNA was observed negative. No hepatitis B recurrence was observed in the 15 cases receiving donor livers of positive anti-HBc. Six cases receiving donor livers of positive HBsAg failed to become negative HBsAg after LT. All the follow-up recipients survived. No HBV DNA replication was observed in the recipients after LT. No adverse reaction of related nucleoside analogues was observed.   Conclusion   It is effective and safe to use nucleoside analogues monotherapy for the prevention of hepatitis B recurrence in patients after LT.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    王向槐,罗红涛.人工肝对乙型病毒性肝炎肝衰竭患者细胞因子的影响[J].器官移植,2012,3(2):112-115,120. http://www.organtranspl.com/browse/detail/qkid/37/id/384.html

    Wang XH, Luo HT. The influence of artificial liver support systems on serum cytokines in patients with liver failure associated with virus B hepatitis[J]. Organ Transplant,2012,3(2):112-115,120. http://www.organtranspl.com/browse/detail/qkid/37/id/384.html
    [2]
    汪根树,李华,张琪,等.替比夫定与HBIG联用预防肝移植术后乙型病毒性肝炎复发的疗效[J].器官移植,2011,2(6):314-316,353. http://www.organtranspl.com/browse/detail/qkid/32/id/550.html

    Wang GS, Li H, Zhang Q, et al. Effect of joint use with telbivudine and hepatitis B immune globulin on prophylaxis of hepatitis B recurrence after liver transplantation[J]. Organ Transplant,2011,2(6):314-316,353. http://www.organtranspl.com/browse/detail/qkid/32/id/550.html
    [3]
    Jiang L, Jiang LS, Cheng NS, et al. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation[J]. World J Gastroenterol,2009,15(20):2489-2499. doi: 10.3748/wjg.15.2489
    [4]
    沈中阳,朱志军,邓永林,等.小剂量HBIg联合核苷类似物预防肝移植术后乙肝复发1506例回顾性分析[J].中华肝胆外科杂志,2011,17(5):364-366.

    Shen ZY, Zhu ZJ, Deng YL, et al. Combination of low-dose HBIg and Nucleoside analogues to prevent recurrent hepatitis B virus after liver transplantation: a retrospective analysis of 1506 cases[J]. Chin J Hepatobiliary Surg,2011,17(5):364-366.
    [5]
    Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation[J]. Gastroenterology,2011,141(4):1212-1219. doi: 10.1053/j.gastro.2011.06.083
    [6]
    俞如胜,江艺,吕立志,等.恩替卡韦联合乙肝免疫球蛋白预防肝移植术后乙肝复发[J].中华肝胆外科杂志,2010,16(10):787-788. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201331005.htm

    Yu RS, Jiang Y, Lyu LZ, et al. Prevention of hepatitis B recurrence after liver transplantation with entecavir in combination with HBV immunoglobulin[J]. Chin J Hepatobiliary Surg,2010,16(10):787-788. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201331005.htm
    [7]
    Angus PW, Patterson SJ, Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis[J]. Hepatology,2008,48(5):1460-1466. doi: 10.1002/hep.22524
    [8]
    易述红,蔡常洁,陆敏强,等. 乙肝患者肝移植术后免疫抑制治疗下拉米夫定耐药的发生和治疗[J].中华普通外科杂志,2006,21(11):801-803. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHPZ200611015.htm

    Yi SH, Cai CJ, Lu MQ, et al. The management of lamivudine resistance in immunocompromised chronic hepatitis B liver transplantation recipient under immunosuppressant therapy[J]. Chin J Gen Surg,2006,21(11):801-803. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHPZ200611015.htm
    [9]
    马毅,邰强,何晓顺,等.肝移植术后乙型肝炎病毒再感染的预防和处理[J].中华外科杂志,2009,47(16):1209-1212. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY200705021.htm

    Ma Y, Tai Q, He XS, et al. Prevention and management of hepatitis B virus reinfection after liver transplantation[J]. Chin J Surg,2009,47(16):1209-1212. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY200705021.htm
    [10]
    Lian JS, Zeng LY, Chen JY, et al. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis[J]. World J Gastroenterol,2013,19(37):6278-6283. doi: 10.3748/wjg.v19.i37.6278
    [11]
    Wang J. Clinical utility of entecavir for chronic hepatitis B in Chinese patients[J]. Drug Des Devel Ther,2013,8:13-24. http://cn.bing.com/academic/profile?id=2087038270&encoded=0&v=paper_preview&mkt=zh-cn
    [12]
    Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis[J]. J Hepatol,2010,52(2):176-182 doi: 10.1016/j.jhep.2009.11.007
    [13]
    姜涛,卢实春,赖威,等. HBsAg阳性供肝和HBcAb阳性供肝在肝移植中的应用[J].中华器官移植杂志,2012,33(4):200-204.

    Jiang T, Lu SC, Lai W, et al. Utilization of liver grafts from hepatitis B surface antigen positive or anti-hepatitis B core positive donors[J]. Chin J Organ Transplant,2012,33(4):200-204.
    [14]
    Chotiyaputta W, Pelletier SJ, Fontana RJ, et al. Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers[J]. Hepatol Int,2010,4(4):707-715. doi: 10.1007/s12072-010-9188-0
    [15]
    张闻辉,邓永林,郑虹,等.肝移植术后新发乙型肝炎病毒感染的临床分析[J].中华器官移植杂志,2012,33(5):295-298. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-ZHYX201210002144.htm

    Zhang WH, Deng YL, Zheng H, et al. Clinical analysis of de novo hepatitis B virus infection after liver transplantation[J]. Chin J Organ Transplant, 2012, 33(5):295-298. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-ZHYX201210002144.htm
    [16]
    Lee S, Kwon CH, Moon HH, et al. Antiviral treatment for hepatitis B virus recurrence following liver transplantation[J]. Clin Transplant, 2013, 27(5):E597-E604. doi: 10.1111/ctr.2013.27.issue-5
    [17]
    李敏如,汪根树,汪国营,等.慢性重型肝炎和肝细胞肝癌患者肝移植围手术期T淋巴细胞亚群及其功能的变化[J/CD]. 中华肝脏外科手术学电子杂志,2013,2(3):153-158.

    Li MR, Wang GS, Wang GY, et al. Changes of T lymphocyte subset and its function in patients with chronic severe hepatitis or hepatocellular carcinoma during the perioperation of liver transplantation[J/CD]. Chin J Hepat Surg: Electronic Edition,2013,2(3):153-158.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (66) PDF downloads(5) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return